Phase 1 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with prostate adenocarcinoma (a specific type of prostate cancer), confirmed by a laboratory test on tissue. Certain rare types of prostate cancer are not allowed, but adenocarcinoma with some mixed features may still be eligible (confirm with trial site).
- People whose prostate cancer has spread (is metastatic) and is no longer responding to hormone-lowering treatment — specifically where the cancer has spread to bones, lymph nodes, or both, but has not clearly spread to internal organs such as the liver or lungs.
- People who have had surgical removal of the testicles, or who are currently receiving ongoing hormone-suppressing therapy (such as a GnRH agonist or antagonist injection) and would continue this throughout the trial.
- People whose PSA (prostate-specific antigen) blood level is 2 ng/mL or higher at the screening stage.
- People who have disease that can be measured or evaluated on scans or tests.
- People who are in relatively good general health, able to carry out daily activities with no or only minimal limitations (as rated on a standard medical scale).
Who may not be able to join:
- People who still have significant side effects from previous cancer treatments that have not recovered to mild or baseline levels, with some exceptions such as hair loss, mild nerve-related symptoms, or a skin condition called vitiligo.
- People who have a known allergy, sensitivity, or intolerance to any ingredient in the trial drugs pasritamig or JNJ-86974680.
- People who have an active infection requiring antibiotic treatment taken by mouth or through a drip within the 7 days before the first trial treatment (preventive antibiotic or antiviral use is generally allowed).
- People who have cancer that has spread to the membranes around the brain or spinal cord, or to the brain itself — unless those brain metastases have been definitively treated, are stable and causing no symptoms for more than 2 weeks, and steroid medication for them has been stopped for at least 2 weeks before starting the trial.
- People with serious underlying health conditions or other circumstances that, in the treating doctor's judgment, could interfere with safely receiving treatment, completing trial assessments, or would otherwise make participation not in the person's best interest.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Janssen Research & Development, LLC Clinical trial, Janssen Research & Development, LLC
Phone: 844-434-4210
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With Adverse Events (AEs) by Severity; Part 1: Number of Participants With Dose-Limiting Toxicity (DLT)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.